The UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts made to involve patients in the drug development process.
Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves1.
COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
